Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib - Nerini‐Molteni, Silvia; Ferrarini, Marina; Cozza, Sara; Caligaris‐Cappio, Federico; Sitia, Roberto (British journal of haematology, 2008)
Keywords: Acetylcysteine - pharmacology; Activating Transcription Factor 4 - metabolism; Antineoplastic Agents - pharmacology; Antioxidants - pharmacology; Biological and medical sciences; Boronic Acids - antagonists & inhibitors; Boronic Acids - pharmacology; Bortezomib; Cell Death - drug effects; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; glutathione; Glutathione - metabolism; Hematologic and hematopoietic diseases; Homeostasis - drug effects; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; multiple myeloma; Multiple Myeloma - metabolism; Multiple Myeloma - pathology; Neoplasm Proteins - metabolism; Nrf2; Oxidation-Reduction - drug effects; Protease Inhibitors - pharmacology; proteasome inhibitors; Pyrazines - antagonists & inhibitors; Pyrazines - pharmacology; redox homeostasis; Transcription Factor CHOP - metabolism; Tumor Cells, Cultured; Antineoplastic agent; Immunopathology; multiple myeloma; Bortezomib; Hematology; Homeostasis; B cell neoplasm; proteasome inhibitors; Malignant hemopathy; redox homeostasis; Lymphoid neoplasm; Myeloma; Sensitivity; Immunoglobulinopathy; Nrf2; Analog; Lymphoproliferative syndrome; Proteasome inhibitor; Dipeptides; Cancer; Glutathione